Cytokinetics Past Earnings Performance
Past criteria checks 0/6
Cytokinetics's earnings have been declining at an average annual rate of -37.2%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 13.6% per year.
Key information
-37.2%
Earnings growth rate
-24.3%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 13.6% |
Return on equity | n/a |
Net Margin | -6,988.6% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Cytokinetics, Incorporated: Buyout Speculation Persists
Apr 01Cytokinetics: CEO Talks Down Buyout Prospects
Mar 16Cytokinetics Steps Up As Prime Target After Aficamten's HCM Triumph (Rating Upgrade)
Jan 12An Intrinsic Calculation For Cytokinetics, Incorporated (NASDAQ:CYTK) Suggests It's 37% Undervalued
Oct 05Analysts Are Betting On Cytokinetics, Incorporated (NASDAQ:CYTK) With A Big Upgrade This Week
May 07Analysts Are Betting On Cytokinetics, Incorporated (NASDAQ:CYTK) With A Big Upgrade This Week
Mar 03Cytokinetics, Incorporated's (NASDAQ:CYTK) Intrinsic Value Is Potentially 100% Above Its Share Price
Jan 20Newsflash: Cytokinetics, Incorporated (NASDAQ:CYTK) Analysts Have Been Trimming Their Revenue Forecasts
Dec 15Cytokinetics: Surprise Adcomm For Omecamtiv Causing Concern
Oct 17Cytokinetics gets monitoring panel's nod to continue phase 3 trial of ALS drug reldesemtiv
Oct 10Cytokinetics (NASDAQ:CYTK) Has Debt But No Earnings; Should You Worry?
Aug 23Revenue & Expenses BreakdownBeta
How Cytokinetics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 8 | -526 | 174 | 0 |
30 Sep 23 | 8 | -527 | 183 | 0 |
30 Jun 23 | 10 | -540 | 192 | 0 |
31 Mar 23 | 98 | -431 | 195 | 0 |
31 Dec 22 | 95 | -389 | 178 | 0 |
30 Sep 22 | 148 | -282 | 158 | 0 |
30 Jun 22 | 151 | -216 | 136 | 0 |
31 Mar 22 | 65 | -258 | 114 | 0 |
31 Dec 21 | 70 | -215 | 97 | 0 |
30 Sep 21 | 22 | -229 | 77 | 0 |
30 Jun 21 | 58 | -156 | 63 | 0 |
31 Mar 21 | 59 | -135 | 56 | 0 |
31 Dec 20 | 56 | -127 | 53 | 0 |
30 Sep 20 | 54 | -114 | 49 | 0 |
30 Jun 20 | 19 | -140 | 47 | 0 |
31 Mar 20 | 22 | -132 | 43 | 0 |
31 Dec 19 | 27 | -122 | 40 | 0 |
30 Sep 19 | 31 | -118 | 37 | 0 |
30 Jun 19 | 36 | -110 | 33 | 0 |
31 Mar 19 | 35 | -105 | 31 | 0 |
31 Dec 18 | 32 | -106 | 31 | 0 |
30 Sep 18 | 22 | -120 | 34 | 0 |
30 Jun 18 | 18 | -131 | 37 | 0 |
31 Mar 18 | 14 | -132 | 38 | 0 |
31 Dec 17 | 13 | -128 | 36 | 0 |
30 Sep 17 | 47 | -80 | 33 | 0 |
30 Jun 17 | 99 | -14 | 30 | 0 |
31 Mar 17 | 102 | 3 | 29 | 0 |
31 Dec 16 | 106 | 16 | 28 | 0 |
30 Sep 16 | 83 | 0 | 27 | 0 |
30 Jun 16 | 32 | -42 | 25 | 0 |
31 Mar 16 | 33 | -41 | 22 | 0 |
31 Dec 15 | 29 | -38 | 20 | 0 |
30 Sep 15 | 41 | -20 | 19 | 0 |
30 Jun 15 | 42 | -17 | 17 | 0 |
31 Mar 15 | 43 | -15 | 17 | 0 |
31 Dec 14 | 47 | -15 | 17 | 0 |
30 Sep 14 | 50 | -17 | 17 | 0 |
30 Jun 14 | 45 | -23 | 16 | 0 |
31 Mar 14 | 38 | -30 | 16 | 0 |
31 Dec 13 | 31 | -34 | 15 | 0 |
30 Sep 13 | 8 | -52 | 15 | 0 |
30 Jun 13 | 6 | -49 | 14 | 0 |
Quality Earnings: CYTK is currently unprofitable.
Growing Profit Margin: CYTK is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CYTK is unprofitable, and losses have increased over the past 5 years at a rate of 37.2% per year.
Accelerating Growth: Unable to compare CYTK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CYTK is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: CYTK's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.